WO1999040925A3 - Hapten-modified tumor cell membranes and their use - Google Patents

Hapten-modified tumor cell membranes and their use Download PDF

Info

Publication number
WO1999040925A3
WO1999040925A3 PCT/US1999/003536 US9903536W WO9940925A3 WO 1999040925 A3 WO1999040925 A3 WO 1999040925A3 US 9903536 W US9903536 W US 9903536W WO 9940925 A3 WO9940925 A3 WO 9940925A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor cell
tumor
compositions
membranes
hapten
Prior art date
Application number
PCT/US1999/003536
Other languages
French (fr)
Other versions
WO1999040925A2 (en
Inventor
David Berd
Takami Sato
Original Assignee
Univ Jefferson
David Berd
Takami Sato
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson, David Berd, Takami Sato filed Critical Univ Jefferson
Priority to AU26869/99A priority Critical patent/AU2686999A/en
Priority to EP99907137A priority patent/EP1054690A2/en
Priority to IL13779199A priority patent/IL137791A0/en
Priority to JP2000531176A priority patent/JP2002502880A/en
Priority to BR9907912-7A priority patent/BR9907912A/en
Priority to CA002320969A priority patent/CA2320969A1/en
Priority to KR1020007009049A priority patent/KR20010041018A/en
Publication of WO1999040925A2 publication Critical patent/WO1999040925A2/en
Publication of WO1999040925A3 publication Critical patent/WO1999040925A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012—Haptens, e.g. di- or trinitrophenyl (DNP, TNP)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to isolated tumor cell membranes, compositions thereof, methods of making the membranes and compositions, and methods of treating cancer. The compositions of the present invention include a composition prepared from a tumor cell which is hapten modified. The tumor cell membranes and compositions of the invention have the properties, when administered to a mammal suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of the mammal, of eliciting an inflammatory immune response against the tumor of the mammal, and of eliciting a delayed-type hypersensitivity response to the tumor of the mammal. The membranes and compositions of the invention also stimulate T cells in vitro. The methods of the present invention are directed to treating cancer comprising administering a therapeutically effective amount of a tumor cell membrane. The present invention is also directed to a method of making a hapten-modified tumor cell membrane and dosage forms containing the membranes.
PCT/US1999/003536 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes and their use WO1999040925A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU26869/99A AU2686999A (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes
EP99907137A EP1054690A2 (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes and their use
IL13779199A IL137791A0 (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes and their use
JP2000531176A JP2002502880A (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes and uses thereof
BR9907912-7A BR9907912A (en) 1998-02-17 1999-02-17 Composition, processes to treat cancer, to elicit T lymphocytes that infiltrate a mammalian tumor, to elicit a delayed hypersensitivity response to a mammalian tumor, and to prepare hapten-modified tumor cell membranes, and, isolated membrane of mammalian tumor cell
CA002320969A CA2320969A1 (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes, and methods of making and using hapten-modified tumor cell membranes
KR1020007009049A KR20010041018A (en) 1998-02-17 1999-02-17 Hapten-Modified Tumor Cell Membranes, And Methods Of Making And Using Hapten-Modified Tumor Cell Membranes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2501298A 1998-02-17 1998-02-17
US09/025,012 1998-02-17

Publications (2)

Publication Number Publication Date
WO1999040925A2 WO1999040925A2 (en) 1999-08-19
WO1999040925A3 true WO1999040925A3 (en) 1999-10-21

Family

ID=21823570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/003536 WO1999040925A2 (en) 1998-02-17 1999-02-17 Hapten-modified tumor cell membranes and their use

Country Status (12)

Country Link
EP (1) EP1054690A2 (en)
JP (1) JP2002502880A (en)
KR (1) KR20010041018A (en)
CN (1) CN1291105A (en)
AR (1) AR015237A1 (en)
AU (1) AU2686999A (en)
BR (1) BR9907912A (en)
CA (1) CA2320969A1 (en)
IL (1) IL137791A0 (en)
PL (1) PL342856A1 (en)
WO (1) WO1999040925A2 (en)
ZA (1) ZA991245B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1067960A2 (en) * 1998-04-09 2001-01-17 Thomas Jefferson University A method of inducing an anti-tumor response against a lung metastasis in a melanoma patient
US6248585B1 (en) 1998-11-19 2001-06-19 Thomas Jefferson University Compositions for preserving haptenized tumor cells for use in vaccines
US7297330B2 (en) 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
JP2004507446A (en) * 2000-02-04 2004-03-11 トーマス・ジェファーソン・ユニバーシティ Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts
US7612251B2 (en) 2000-09-26 2009-11-03 Pioneer Hi-Bred International, Inc. Nucleotide sequences mediating male fertility and method of using same
JP2005528901A (en) * 2002-06-10 2005-09-29 アバクス・テクノロジーズ・インコーポレーテッド Cryopreservation of haptenized tumor cells
WO2017189281A1 (en) * 2016-04-27 2017-11-02 The Regents Of The University Of Michigan C3d cellular and acellular vaccines for the prevention and treatment of cancer
CN115137814A (en) * 2022-07-01 2022-10-04 可蓝赛生物医药(上海)有限公司 Tumor vaccine adjuvant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040173A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Hapten modified tumor cell extract and methods of treating or screening for cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4086134A (en) * 1973-09-18 1978-04-25 University Of Glasgow Method for preparation of vaccine against feline leukemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040173A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Hapten modified tumor cell extract and methods of treating or screening for cancer

Also Published As

Publication number Publication date
IL137791A0 (en) 2001-10-31
EP1054690A2 (en) 2000-11-29
CA2320969A1 (en) 1999-08-19
AU2686999A (en) 1999-08-30
WO1999040925A2 (en) 1999-08-19
BR9907912A (en) 2000-10-24
KR20010041018A (en) 2001-05-15
AR015237A1 (en) 2001-04-18
ZA991245B (en) 1999-08-18
JP2002502880A (en) 2002-01-29
PL342856A1 (en) 2001-07-16
CN1291105A (en) 2001-04-11

Similar Documents

Publication Publication Date Title
Park et al. Chaga mushroom extract inhibits oxidative DNA damage in human lymphocytes as assessed by comet assay
Brush et al. The effect of Echinacea purpurea, Astragalus membranaceus and Glycyrrhiza glabra on CD69 expression and immune cell activation in humans
Huang et al. Orally administered mycelial culture of Phellinus linteus exhibits antitumor effects in hepatoma cell-bearing mice
EP2269656A3 (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO1999040925A3 (en) Hapten-modified tumor cell membranes and their use
WO1999056773A3 (en) Composition comprising tumor cells and extracts and method of using thereof
KR20070059062A (en) A purified arabinogalactan-protein (agp) composition
WO2000057911A3 (en) Hapten-conjugated mammalian cells and methods of making and using thereof
JP2005510543A (en) Therapeutic treatment
WO2002032378A3 (en) Fusion cells and cytokine compositions for treatment of disease
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
CN103087215B (en) Method for extracting and purifying antitumor polysaccharide components in sargassum muticum
Mo et al. ROS scavenging nanozyme modulates immunosuppression for sensitized cancer immunotherapy
WO2011039629A2 (en) Bioactive fraction of petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer
Lee et al. Inhibition of leukemia proliferation by a novel polysaccharide identified from Monascus-fermented dioscorea via inducing differentiation
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1211311A3 (en) Cord blood-derived activated lymphocytes and preparations containing said lymphocytes
WO2005014008A3 (en) Treatment of disorders associated with natural killer t cells
Balm et al. Mononuclear phagocyte function in head and neck cancer. Chemotactic responsiveness of blood monocytes in correlation between histologic grade of the tumor and infiltration of these cells into the tumor area
Sunila et al. Protective effect of Thuja occidentalis against radiation-induced toxicity in mice

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99803065.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 506026

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 137791

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 26869/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2320969

Country of ref document: CA

Ref document number: 2320969

Country of ref document: CA

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 531176

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1999907137

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/007995

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020007009049

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999907137

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007009049

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1999907137

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007009049

Country of ref document: KR